This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting and is pleased to share the following Emerging Science abstracts, which qualified by having key aspects of research conducted after the October 26, 2015 abstract submission deadline. They are new and of sufficient scientific importance to warrant expedited presentation and publication.
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Efficacy of eslicarbazepine acetate versus controlled-release carbamazepine as monotherapy in patients with newly diagnosed partial-onset seizures
- Safety and tolerability of eslicarbazepine acetate as monotherapy in patients with newly diagnosed partial-onset seizures
- Cerebrospinal fluid findings in Ebola survivors with neurological sequelae
- Neurologic manifestations of arboviruses in the epidemy of Pernambuco, Brazil
- Incidence of traumatic brain injury (TBI) in retired NFL players. Correlation with diffusion tensor (DTI) MRI and neuropsychological testing
- Sports related concussion diagnosis using advanced measures of cerebrovascular reactivity
- Effect of propranolol and clonidine on mechanically ventilated patients with severe traumatic brain injury: The dash after TBI randomized control trial
- Positive phase II double-blind randomized placebo-controlled crossover trial of clemastine fumarate for remyelination of chronic optic neuropathy in MS
- Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): Results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial
- ADVANCE phase 3 extension study (ATTAIN): Peginterferon beta-1a 125 mcg every 2 weeks demonstrated sustained efficacy in RMS patients treated up to 5 years
- Evaluation of the NEDA (No Evidence of Disease Activity) measure for predicting long-term outcomes from the pivotal trial of interferon beta-1b in multiple sclerosis
- GDF-15, lactate as well as clinical grading scale was improved by sodium pyruvate therapy in mitochondrial myopathy
- Orally-administered TRPV1 and TRPA1 activators reduce night leg cramps in a randomized, blinded, placebo-controlled, crossover human trial
- ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 ease lid study
- Adjunctive everolimus therapy for the treatment of refractory seizures associated with tuberous sclerosis complex: Results from a randomized, placebo-controlled, phase 3 trial
- ADVANCE phase 3 extension study (ATTAIN): Peginterferon beta-1a safety and tolerability remains favorable in RMS patients with up to 5 years of treatment
- Post hoc results from PREFERMS: Volumetric MRI outcomes adjusted for exposure to fingolimod versus platform injectable disease-modifying therapies in early relapsing–remitting multiple sclerosis
- Marked reduction in secondarily generalized seizures (SGS) in patients treated with perampanel for 3 and 4 years
- Neuroprotective and oligodendrocyte precursor cell differentiation promoting activities of the RXR nuclear receptor agonist IRX4204 are potentiated by thyroid hormone
- Four-year longitudinal index stability data from STRATIFY-2 support the clinical utility of index for risk stratification of natalizumab-associated progressive multifocal leukoencephalopathy
- Natalizumab’s effects on peripheral immune cells in patients with multiple sclerosis (MS) are reversible by 16-20 weeks after treatment discontinuation
- Info & Disclosures
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg